Human Longevity Has Cut Genomic Sequencing Costs

The company now offers whole-genome sequencing for $599 as it shifts its focus toward predictive health models.

Updated on Oct. 1, 2026 in Healthcare

Human Longevity Has Cut Genomic Sequencing Costs

Live Poll

Do you trust AI-driven models to accurately predict and improve your personal long-term health outcomes?

Human Longevity Inc. has lowered the price of its direct-to-consumer whole-genome sequencing to $599. The move marks a pivot in the company's strategy to expand access to data-driven preventive medicine.

Why it matters

The company aims to shorten the time individuals spend in declining health by shifting the medical paradigm toward predictive, data-driven prevention. This strategy leverages extensive datasets to identify risks before they manifest as severe illness.

Human Longevity Inc. now offers whole-genome sequencing for $599, a significant reduction from its previous $8,000 executive health program. The firm has raised $500 million in total funding and maintains a dataset of over 10,000 phenotyped clients.

The players

Human Longevity Inc.

This company is a health-tech organization that utilizes large-scale data and genomics to focus on preventive medicine.

Wei-Wu He

He is the individual who took operational control of Human Longevity Inc. in 2019 and has invested $70 million into the company.

Human Life Foundation Models, Inc.

This entity was spun out of Human Longevity Inc. in May 2026 to focus on advanced artificial intelligence development.

Insilico Medicine

This company is a biotechnology firm that has entered into a multi-year co-development agreement with Human Life Foundation Models, Inc.

The details

The company uses integrated AI models to analyze genomic data, blood biomarkers, imaging, and information from wearables. Members are further supported by a $1 million financial guarantee provided if they develop missed stage-four prostate or pancreatic cancer.

Human Longevity Inc. was founded in 2013.
Wei-Wu He took operational control of the company in 2019.
Human Life Foundation Models, Inc. was spun out in May 2026.

Market Landscape

Human Longevity Inc. is shifting the competitive environment by applying large-scale AI modeling to individual health data, effectively moving away from high-cost boutique medical offerings. The creation of Human Life Foundation Models, Inc. signals an industry-wide pivot toward using deep learning to achieve predictive health outcomes.

Patients now have access to comprehensive genome sequencing at a lower price point than previously available executive programs. This change allows individuals to incorporate advanced biomarker and wearable data into their personal health management routines.

The takeaway

The transition to lower-cost genomic sequencing reflects a broader movement toward making precision medicine a standard part of personal wellness. Consumers should view these services as data-gathering tools that supplement, rather than replace, traditional medical diagnostic care.